AAAAI 2020 Annual Meeting
AAAAI Annual Meeting

Sponsored Programs

These programs are not sponsored or programmed by the AAAAI.

A number of sponsored programs that were originally scheduled as Non-CME Educational Programs during the 2020 AAAAI Annual Meeting have been or will be converted into virtual formats. Some will be live virtual events, while others will be recordings that you can access at your convenience, and some will offer CME by accredited providers other than the AAAAI.

Please see below for a listing of these programs with further details on how to participate. The page will be updated as more programs are available.

DUPIXENT® Webcast
Presented by Sanofi Genzyme and Regeneron

Wednesday, June 3 and June 10, 2020, 7:00 PM ET
To Register for this event, please visit: https://bit.ly/2KW39P7

Listen to an expert clinician discuss data from 2 distinct clinical development programs. Join these educational events to learn more. June 3 Presented by Ellen Sher, MD and June 10 Presented by Cedric “Jamie” Rutland, MD.

________________________________________________________________________________________________

Live Virtual CME Webinar and Case Discussion

AIRING IT OUT: A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyps

Thursday, June 11, 2020
5:00 pm – 6:30 pm ET / 4:00 pm – 5:30 pm CT / 2:00 pm – 3:30 pm PT

July 2020
Coming Soon!

August 2020
Coming Soon!

REGISTER NOW! ExchangeCME.com/project/AsthmaSeries/

Faculty: Joseph K. Han, MD; John J. Oppenheimer, MD; Reynold A. Panettieri, Jr, MD

This Case-in-Point™ live virtual webinar series focuses on the management of moderate-to-severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Each segment of the activity will open with a brief multimedia presentation of a clinical case, highlighting the patient’s unique past medical history, current management challenges, and persistent, daily burdens. Expert faculty will guide learners through each case, sharing relevant guideline recommendations, published data, and clinical insights. Participants will have an opportunity to directly ask questions to the faculty panel through a brief Q&A session at the end of the webinar. Please join us for this informative and engaging virtual live webinar series and check back frequently for additional program times!

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, and jointly provided by Postgraduate Institute for Medicine (PIM) and Integritas Communications.

________________________________________________________________________________________________

Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

An Interactive Live CME Webcast and Case Simulation
Choose from 4 different dates and times!

Thursday, June 11, 2020
8:00 PM – 9:00 PM (ET)

Wednesday, July 15, 2020
9:00 PM – 10:00 PM (ET)

Thursday, September 17, 2020
8:00 PM – 9:00 PM (ET)

Tuesday, September 29, 2020
9:00 PM – 10:00 PM (ET)

Until recently, treatment options for severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome were limited mostly to immunosuppression with oral corticosteroids (OCS) or other systemic agents. An expanding understanding of the pathophysiology of these diseases has led to the identification of newer therapeutic targets and more selective and better tolerated treatments for eosinophil reduction.

This interactive webcast will review strategies for recognizing these phenotypes of severe eosinophilic diseases of the lungs and help the clinician better navigate available treatments in order to improve symptoms, lighten the disease burden, and reduce exacerbations and OCS reliance for patients with severe asthma and associated eosinophil-mediated conditions.  

For complete details or to register, visit: www.integrityce.com/asthma

This CME activity is provided by Integrity Continuing Education.
This activity is supported by an educational grant from GlaxoSmithKline.

________________________________________________________________________________________________

Date: June 23, 2020 – Live Virtual Presentation
Time: 12:00 PM – 1:00 PM EDT, 11:00 AM – 12:00 PM CDT, 10:00 AM – 11:00 AM MDT, 9:00 AM – 10:00 AM PDT
Sponsor: Sponsored by Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Title: DUPIXENT® (dupilumab) Product Presentation
Description: Come learn about clinical efficacy, safety information, MOA, dosing and administration, and how DUPIXENT may help your appropriate patients.
Presented by: Kathryn Sowerwine, MD, Reston, Virginia
Registration: Registration details are coming soon. Check back for more information, or email allergyevents@significantmeetings.com to receive more information once available.

________________________________________________________________________________________________

On Demand Videos
Available Now

Clinical Data and Insights for Using a Biologic to Manage Severe Eosinophilic Asthma

Sponsored by GSK

Please follow the link for 3 short excerpts where medical experts Dr. Jacqueline Eghari-Sabet, Dr. Shahnaz Fatteh, and Dr. Yaron Goldman deliver case driven presentations to highlight the clinical features of Severe Eosinophilic Asthma and a biologic treatment. Each guest speaker will cover key aspects of severe patient types that may help determine when a biologic therapy could be an effective treatment option. Watch on-demand anytime.

Watch at: gskvideoresources.com

________________________________________________________________________________________________

Live Virtual Symposium
Thursday, May 21, 2020
12:00-1:00 pm ET / 11:00 am-12:00 pm CT / 9:00-10:00 am PT

A Virtual Reality View: New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

Register now: https://www.medlearninggroup.com/cme-programming/ad-pa/


Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK